Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®

  • Read more about Bone Therapeutics Authorised to Enrol patients in the UK in Pivotal Phase III Osteonecrosis Trial with PREOB®

Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product

  • Read more about Bone Therapeutics Expands Product Portfolio with New Research into Innovative Combined Cell-Matrix Product

Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris

  • Read more about Bone Therapeutics Announces Intention to Launch an Initial Public Offering on Euronext Brussels and Euronext Paris

Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial

  • Read more about Bone Therapeutics Demonstrates Efficacy in First Patient Cohort in ALLOB® Phase I/IIA Delayed-Union Trial

Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris

  • Read more about Bone Therapeutics Launches its Initial Public Offering on Euronext Brussels and Euronext Paris

Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris

  • Read more about Bone Therapeutics raises EUR32.2M in a 2.5x oversubscribed successful Initial Public Offering on Euronext Brussels and Euronext Paris

Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million

  • Read more about Full exercise of Over-allotment Option: Total proceeds from the Initial Public Offering increased to €37 million

Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015

  • Read more about Bone Therapeutics to participate in key investor and partnering conferences in the first half of 2015

Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA

  • Read more about Transparency notification received from S.R.I.W. & Sofipôle, Mr J. Reymann, SFPI SA and Theodorus II SA

Bone Therapeutics announces its financial calendar for 2015

  • Read more about Bone Therapeutics announces its financial calendar for 2015

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions